With this premise, Zheng, Zhu and coworkers decided to synthesize novel derivatives (31 and 32) of Sorafenib, bis-aryl urea with remarkable biological properties [173, 174], replacing this group with a pyrazole moiety to evaluate the influence of the change on the cytotoxicity against several cancer cell lines (A549, HepG2, MCF-7, and PC-3) and kinases (VEGFR-2/KDR, BRAF, CRAF, c-Met, EGFR and Flt-3) (Fig. 22) [175]. The gene discussed is KDR; the disease is cancer.